Potentials and limitations of pharmaceutical and pharmacological applications of bile acids in hearing loss treatment
Hearing loss is a worldwide epidemic, with approximately 1.5 billion people currently struggling with hearing-related conditions. Currently, the most wildly used and effective treatments for hearing loss are primarily focus on the use of hearing aids and cochlear implants. However, these have many limitations, highlighting the importance of developing a pharmacological solution that may be used to overcome barriers associated with such devices. Due to the challenges of delivering therapeutic agents to the inner ear, bile acids are being explored as potential drug excipients and permeation enhancers. This review, therefore, aims to explore the pathophysiology of hearing loss, the challenges in treatment and the manners in which bile acids could potentially aid in overcoming these challenges.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Therapeutic delivery - (2023) vom: 21. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lewkowicz, Michael [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bile acids |
|---|
| Anmerkungen: |
Date Revised 16.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.4155/tde-2022-0033 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353094374 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353094374 | ||
| 003 | DE-627 | ||
| 005 | 20240216232515.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2022-0033 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1295.xml |
| 035 | |a (DE-627)NLM353094374 | ||
| 035 | |a (NLM)36803017 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lewkowicz, Michael |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potentials and limitations of pharmaceutical and pharmacological applications of bile acids in hearing loss treatment |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Hearing loss is a worldwide epidemic, with approximately 1.5 billion people currently struggling with hearing-related conditions. Currently, the most wildly used and effective treatments for hearing loss are primarily focus on the use of hearing aids and cochlear implants. However, these have many limitations, highlighting the importance of developing a pharmacological solution that may be used to overcome barriers associated with such devices. Due to the challenges of delivering therapeutic agents to the inner ear, bile acids are being explored as potential drug excipients and permeation enhancers. This review, therefore, aims to explore the pathophysiology of hearing loss, the challenges in treatment and the manners in which bile acids could potentially aid in overcoming these challenges | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a bile acids | |
| 650 | 4 | |a cochlea implants | |
| 650 | 4 | |a hearing aids | |
| 650 | 4 | |a hearing loss | |
| 650 | 4 | |a pathophysiology of hearing loss | |
| 700 | 1 | |a Jones, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Kovacevic, Bozica |e verfasserin |4 aut | |
| 700 | 1 | |a Ionescu, Corina Mihaela |e verfasserin |4 aut | |
| 700 | 1 | |a Wagle, Susbin Raj |e verfasserin |4 aut | |
| 700 | 1 | |a Foster, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Mikov, Momir |e verfasserin |4 aut | |
| 700 | 1 | |a Mooranian, Armin |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Salami, Hani |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic delivery |d 2010 |g (2023) vom: 21. Feb. |w (DE-627)NLM203937082 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:21 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/tde-2022-0033 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 21 |c 02 | ||